Esperion Therapeutics (NASDAQ:ESPR) had its price target increased by stock analysts at Chardan Capital from $20.00 to $75.00 in a note issued to investors on Wednesday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Chardan Capital’s price target would indicate a potential upside of 41.14% from the stock’s previous close.

A number of other research firms have also commented on ESPR. Northland Securities started coverage on shares of Esperion Therapeutics in a research report on Tuesday, August 29th. They issued an “outperform” rating and a $72.00 price objective for the company. Jefferies Group restated a “buy” rating and issued a $85.00 price objective on shares of Esperion Therapeutics in a research report on Monday, August 21st. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Cowen initiated coverage on shares of Esperion Therapeutics in a research report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price objective for the company. Finally, Needham & Company LLC raised their target price on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research note on Tuesday, August 8th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $60.15.

Esperion Therapeutics (ESPR) traded down $5.51 during mid-day trading on Wednesday, hitting $53.14. 1,581,675 shares of the stock were exchanged, compared to its average volume of 1,025,290. Esperion Therapeutics has a one year low of $10.71 and a one year high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter in the prior year, the company posted ($0.77) EPS. analysts predict that Esperion Therapeutics will post -7.21 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its stake in Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 4,856 shares in the last quarter. Aperio Group LLC purchased a new stake in Esperion Therapeutics in the second quarter valued at approximately $249,000. SG Americas Securities LLC raised its stake in Esperion Therapeutics by 74.5% in the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 2,991 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 806 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY purchased a new position in shares of Esperion Therapeutics during the first quarter worth approximately $385,000. 92.27% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/06/chardan-capital-increases-esperion-therapeutics-espr-price-target-to-75-00.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.